Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2868 and Anlotinib with Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma
NCT07165951Phase 3Recruiting
- Sponsor
- Chia Tai Tianqing
- Start
- Dec 2025
- Primary completion
- May 2028
- Modality
- Immunotoxins, Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pancreatic ductal adenocarcinoma (PDAC) comparing TQB2868 + Anlotinib + Chemotherapy with Placebo + Anlotinib + Chemotherapy (2 arms). Primary endpoint: Overall Survival at 2 years. Started Dec 2025; status: recruiting.
02
Drugs
TQB2868
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07165951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07165951.